{"id":4340,"date":"2026-11-14T09:00:00","date_gmt":"2026-11-14T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4340"},"modified":"2026-11-17T20:41:51","modified_gmt":"2026-11-18T00:41:51","slug":"avexitide-reduces-severe-post-bariatric-hypoglycemia","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4340","title":{"rendered":"Avexitide Reduces Severe Post Bariatric Hypoglycemia"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Amylyx_Avexitide_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4348\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Amylyx_Avexitide_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Amylyx_Avexitide_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Amylyx_Avexitide_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Amylyx_Avexitide_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_Amylyx_Avexitide_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Amylyx Pharmaceuticals<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Randomized Phase 3 results (LUCIDITY)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Peptide (GLP-1 receptor antagonist)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Avexitide<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>GLP-1 receptor<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Post-bariatric hypoglycemia<\/p>\n<h4>Summary<\/h4>\n<p>Amylyx detailed the randomized Phase 3 LUCIDITY trial: avexitide reduced the composite Level 2\/3 hypoglycemic-event rate by 55% versus placebo over 16 double-blind weeks. This is a previously missed November 14 release with November 15 conference presentation, not a new November 16 trial result.<\/p>\n<p>Seventy-eight adults with post-bariatric hypoglycemia after Roux-en-Y bypass were randomized 3:2 to daily 90 mg avexitide or placebo, alongside diet management. Least-squares mean events were 0.55 versus 1.24 per week; p=0.0000034. Prespecified secondary reductions were 63% for SMBG-confirmed Level 2, 47% for adjudicated Level 3 and 42% for CGM-detected Level 2 events. No deaths or treatment-related serious adverse events were reported in the double-blind period.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>GLP-1 receptor antagonism may blunt exaggerated post-meal insulin secretion after bypass. <strong>Interpretation A:<\/strong> consistent multiplicity-controlled endpoints and objective glucose measures support clinical benefit in a disorder without a labeled drug. A randomized blinded design strengthens causality. Counterpoint: n=78 and 16 weeks do not establish long-term effects, adherence or use in other bariatric procedures.<\/p>\n<p><strong>Interpretation B:<\/strong> high baseline event frequency and intensive monitoring could influence absolute event rates, though the placebo-controlled between-arm differences counter that explanation. Daily injection burden, nutrition variability, severe-event adjudication and real-world CGM use will affect translation. No superiority over off-label approaches is shown.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Post-bariatric hypoglycemia can follow Roux-en-Y bypass when exaggerated incretin signaling drives postprandial insulin and low glucose. Avexitide is a GLP-1 receptor antagonist intended to dampen that pathway.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Company-presented Phase 3 data verified.<\/li>\n<li>Missing: full protocol and subgroup analysis, long-term open-label durability, detailed adverse-event table and regulatory plan.<\/li>\n<li>Upgrade: durable severe-event reduction and FDA acceptance; downgrade: loss of effect or tolerability problems with chronic dosing.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The controlled result is a material metabolic-disease signal, with external validity and long-term burden still unresolved.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amylyx detailed the randomized Phase 3 LUCIDITY trial: avexitide reduced the composite Level 2\/3 hypoglycemic-event rate by 55% versus placebo over 16 double-blind weeks. This is a previously missed November 14 release with November&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4348,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[370,371,372],"class_list":["post-4340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-amylyx-pharmaceuticals","tag-avexitide","tag-post-bariatric-hypoglycemia"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4340"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4340\/revisions"}],"predecessor-version":[{"id":4356,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4340\/revisions\/4356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4348"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}